Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080142 · ClinicalTrials.gov registry record · Phase 4
TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery
A Phase 4 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT03080142 is a Phase 4 study that has completed, run by University of California, Davis. The registered enrollment target is 86 participants.
The verdict
NCT03080142, a Phase 4 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
This is a prospective randomized study designed to compare the pain control from a single shot of liposomal bupivacaine (Exparel) against transversus abominus plane (TAP) catheters with ropivicaine bolus in patients undergoing elective colorectal surgery.
Interventions
- DRUG Exparel
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2019-05-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03080142
The ClinicalTrials.gov registry entry for NCT03080142 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT03080142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03080142 about?
NCT03080142 is a clinical study titled "TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery". This is a prospective randomized study designed to compare the pain control from a single shot of liposomal bupivacaine (Exparel) against transversus abominus plane (TAP) catheters with ropivicaine bolus in patients undergoing elective colorectal surgery.
What is the current status of trial NCT03080142?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2017-03-01. Estimated completion is 2019-05-29.
What interventions are being tested in trial NCT03080142?
The interventions under investigation include: Exparel (DRUG), Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT03080142?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.